David Sykes
Internal Medicine · Boston, MANPI 1851323380
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,827 of the $32,441 with a category attached, or 70.4%. 9 manufacturers reported payments, led by Aurobindo Pharma USA, Inc. at 59.7% of the total. Reporting peaked in 2024 at $24,379 and has fallen 98.8% since, to $288 in 2025. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $720.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurobindo Pharma USA, Inc.$19K
- Philips North America LLC$8K
- Mylan Inc.$4K
- Bristol Myers Squibb$576
- Sanofi$209
- Agios Pharmaceuticals, Inc.$123
- plus $153 from 3 others
What the payments were for
- Consulting fees$22,82770%
- Speaking & faculty fees$7,70024%
- Travel & lodging$1,1824%
- Food & beverage$7312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurobindo Pharma USA, Inc. | 8 | $19,378 |
| Philips North America LLC | 4 | $7,700 |
| Mylan Inc. | 26 | $4,302 |
| Bristol Myers Squibb | 1 | $576 |
| Sanofi | 2 | $209 |
| Agios Pharmaceuticals, Inc. | 1 | $123 |
| Amgen | 1 | $74 |
| Recordati_rare_diseases_inc. | 1 | $62 |
| Teleflex LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clozapine$22,988
- (9494) consulting service$7,700
- WAYRILZ$125
- PYRUKYND$123
How this compares
$32,441 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $52,276 |
| XareltoRivaroxaban | 11 | $15,909 |
| Hydroxyurea | 18 | $776 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.